Patents by Inventor Said Sebti

Said Sebti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070161613
    Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.
    Type: Application
    Filed: February 7, 2007
    Publication date: July 12, 2007
    Inventors: Heidi Kay, Jay Palmer, Joseph Stanko, Said Sebti
  • Publication number: 20070123502
    Abstract: The invention disclosed herein provides methods for diagnosing and treating diseases and/or conditions associated with dysregulated Stat3-mediated activity.
    Type: Application
    Filed: December 23, 2005
    Publication date: May 31, 2007
    Applicant: University of South Florida
    Inventors: James Turkson, Richard Jove, Said Sebti
  • Publication number: 20070060521
    Abstract: Signal Transducer and Activator of Transcription (STAT) proteins have a fundamental role cell signaling, and are activated by a large number of cytokines and growth factors. One member of the STAT family, STAT3, has a critical role in oncogenesis. The present invention relates generally to disruption of the pathway of STAT3 signaling in the treatment of human cancer. STAT3 activation is shown to be present in diverse tumor cell lines and tumors, to promote oncogenesis, to inhibit apoptosis, and to reduce sensitivity to chemotherapeutic agents. Inhibition of STAT3 signaling induces apoptosis specifically in tumor cell lines, and increases sensitivity to chemotherapeutic agents. The invention relates more particularly to methods, compositions, means of administering such compositions, and means for identifying such compositions for the inhibition of STAT3 intracellular signaling in the treatment of human cancers.
    Type: Application
    Filed: August 28, 2006
    Publication date: March 15, 2007
    Inventors: Richard Jove, William Dalton, Said Sebti, Hua Yu, Richard Heller, Mark Jaroszeski, Richard Gilbert, Andrew Hamilton
  • Publication number: 20070021512
    Abstract: The invention disclosed herein provides for methods of treating cancer using inhibitors of the Raf/Mek/P-Erk 1/2 pathway. These inhibitors include B2AR agonists (such as ARA-211 (pirbuterol) and isoproterenol), adenylyl cyclase activators, cAMP analogs and Epac activators. The invention also provides methods for diagnosing cancer in an individual.
    Type: Application
    Filed: July 21, 2006
    Publication date: January 25, 2007
    Inventor: Said Sebti
  • Patent number: 7157419
    Abstract: Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: January 2, 2007
    Assignee: University of South Florida
    Inventors: Said Sebti, Andrew D. Hamilton
  • Publication number: 20060287237
    Abstract: The present invention concerns the use of the protein RhoB and its variants to inhibit cancer cell growth, migration, invasion, metastasis, malignant cell transformation, and/or to modulate oncogenic signaling, wherein introducing RhoB directly, or indirectly via a nucleic acid sequence encoding RhoB, into a malignantly transformed cell or a cancerous cell decreases phosphorylation of Erk and Akt proteins inhibiting the PI3-kinase/Akt cell survival pathway and promoting apoptotic cell death. In one aspect, the compositions and methods of the present invention are used to inhibit the malignant transformation of cells by the oncogenes H-Ras, N-Ras, K-Ras, EGFR, or ErbB2, or to inhibit the growth of cancer cells transformed by such oncogenes. The compositions and methods of the present invention may be used to inhibit cancer cell growth, inhibit malignant cell transformation, and modulate oncogenic signaling in vivo or in vitro.
    Type: Application
    Filed: August 30, 2006
    Publication date: December 21, 2006
    Inventor: Said Sebti
  • Publication number: 20060247188
    Abstract: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
    Type: Application
    Filed: March 29, 2005
    Publication date: November 2, 2006
    Applicant: University of South Florida
    Inventors: Jin Cheng, Said Sebti
  • Publication number: 20060105374
    Abstract: In one aspect, the present invention concerns RhoB variant polypeptides and isolated degenerate polynucleotides encoding the RhoB variant polypeptides. In another aspect, the present invention concerns nucleic acid constructs containing a polynucleotide encoding a RhoB variant polypeptide, and host cells genetically modified to express such polynucleotides. In another aspect, the present invention provides a method of inhibiting the growth of, and inducing apoptosis in, cancerous cells by contacting the cells with an effective amount of a RhoB variant.
    Type: Application
    Filed: November 14, 2005
    Publication date: May 18, 2006
    Inventor: Said Sebti
  • Publication number: 20060084596
    Abstract: Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors.
    Type: Application
    Filed: September 14, 2005
    Publication date: April 20, 2006
    Inventors: Said Sebti, Andrew Hamilton
  • Publication number: 20060030536
    Abstract: Compositions and methods for treating cancer and proliferative angiopathies are provided. A composition can include an inhibitor of the Jak2/Stat3 signaling pathway and an inhibitor of the PI3k/Akt signaling pathway. In certain cases, the two inhibitors are capable of acting synergistically as compared to either inhibitor alone.
    Type: Application
    Filed: April 8, 2005
    Publication date: February 9, 2006
    Applicant: University of South Florida
    Inventors: Hua Yu, Richard Jove, Jin Cheng, Guilian Niu, Said Sebti
  • Publication number: 20050288365
    Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.
    Type: Application
    Filed: January 6, 2005
    Publication date: December 29, 2005
    Inventors: Heidi Kay, Jay Palmer, Joseph Stanko, Said Sebti
  • Publication number: 20050197401
    Abstract: Growth factor binding compounds having a plurality of acyclic isophthalic acid groups attached to a non-peptide organic scaffold and pharmaceutical compositions of the same are disclosed. Methods of administering and using the growth factor binding compounds or the growth factor binding compositions are also taught. These novel growth factor binding compounds are useful for treating angiogenesis, excessive cellular proliferation, tumor growth, and a combination thereof as well as inhibiting growth factor binding to cells and phosphorylation.
    Type: Application
    Filed: January 27, 2005
    Publication date: September 8, 2005
    Inventors: Said Sebti, Andrew Hamilton, Rishi Jain
  • Publication number: 20050004009
    Abstract: The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics that inhibit STAT function. Peptidomimetics of the invention include compounds of the formula RY*L (where Y* represents phosphotyrosine), with the R group at the Y-1 position. Peptidomimetics of the invention disrupt Stat3 activation and function. Peptidomimetics of the invention significantly inhibit tumor cell growth and induce tumor cell death.
    Type: Application
    Filed: February 20, 2004
    Publication date: January 6, 2005
    Inventors: James Turkson, Richard Jove, Said Sebti, Andrew Hamilton
  • Publication number: 20030118589
    Abstract: Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors.
    Type: Application
    Filed: March 21, 2001
    Publication date: June 26, 2003
    Inventors: Said Sebti, Andrew D. Hamilton
  • Patent number: 6011175
    Abstract: A compound of the formulaC.sup.0 BwhereinC.sup.0 stands for ##STR1## A representing O or 2H, and R.sub.0 representing SH, NH.sub.2, or C.sub.x H.sub.y --SO.sub.2 --NH--, wherein C.sub.x H.sub.y is a straight chain saturated or unsaturated hydrocarbon, with x being between 1 and 20 and y between 3 and 41, inclusive; andB stands for --NHR, where R is an aryl group.The compounds are useful for inhibiting p21ras farnesyltransferase.
    Type: Grant
    Filed: January 2, 1996
    Date of Patent: January 4, 2000
    Assignee: University of Pittsburgh
    Inventors: Said Sebti, Andrew Hamilton
  • Patent number: 5965539
    Abstract: Compounds which inhibit prenyl transferases, particularly farnysyltransferase and geranylgeranyl transferase I, processes for preparing the compounds, pharmaceutical compositions containing the compounds, and methods of use.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: October 12, 1999
    Assignee: Univeristy of Pittsburgh
    Inventors: Said Sebti, Andrew Hamilton
  • Patent number: 5856310
    Abstract: Peptidomimetics of the formula C-AMBA-X where C is cysteine, X is, for example, methionine or phenylalanine and AMBA is a hydrophobic spacer, notably 3-aminomethylbenzoic acid. These compounds are effective inhibitors of p21ras farnesyltransferase. Other modifications including alternative spacers for AMBA, and replacement of the A.sub.1 A.sub.2 X component of known CA.sub.1 A.sub.2 X tetrapeptides by a non-peptide aryl or heterocyclic component are also disclosed as are various phosphorylated and arylated derivatives of peptides and peptidomimetics. Pro-drugs made by functionalizing terminal amino and carboxylic acid groups of peptides and peptidomimetics are also disclosed. Such functionalized derivatives demonstrate increased cell uptake. Other structural modifications are also referred to.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 5, 1999
    Assignee: University of Pittsburgh
    Inventors: Said Sebti, Andrew Hamilton, Churl Min Seong
  • Patent number: 5705686
    Abstract: A compound of the formulaC.sup.1 Rwhere C.sup.1 is 3-mercapto-2-amino-propylamino and R is an aryl group. The compounds are useful for inhibiting p21ras farnesyltransferase.
    Type: Grant
    Filed: January 12, 1995
    Date of Patent: January 6, 1998
    Assignee: University of Pittsburgh
    Inventors: Said Sebti, Andrew Hamilton
  • Patent number: 5602098
    Abstract: Peptidomimetics of the formula C-AMBA-X where C is cysteine, X is, for example, methionine or phenylalanine and AMBA is a hydrophobic spacer, notably 3-aminomethylbenzoic acid. These compounds are effective inhibitors of p21 ras farnesyltransferase. Other modifications including alternative spacers for AMBA, and replacement of the A.sub.1 A.sub.2 X component of known CA.sub.1 A.sub.2 X tetrapeptides by a non-peptide aryl or heterocyclic component are also disclosed as are various phosphonylated and arylated derivatives of peptides and peptidomimetics. Pro-drugs made by functionalizing terminal amino and carboxylic acid groups of peptides and peptidomimetics are also disclosed. Such functionalized derivatives demonstrate increased cell uptake. Other structural modifications are also referred to.
    Type: Grant
    Filed: May 18, 1993
    Date of Patent: February 11, 1997
    Assignee: University of Pittsburgh
    Inventors: Said Sebti, Andrew Hamilton, Churl M. Seong